Heart Failure Treatment

Hemostemix’s ACP-01 therapy, a novel cellular treatment for heart failure, has been detailed in a peer-reviewed paper. Targeting non-ischemic dilated cardiomyopathy, ACP-01 utilizes autologous cells to combat inflammation, fibrosis, and improve blood flow. Earlier studies showed significant improvement in cardiac function, with LVEF increases up to 47.1% in DCM patients. The therapy is now available in Florida under new legislation, offering a promising option for patients with limited alternatives.